FINNENCE ▪ THE WIRE FILE
THE WIRE · № 71556
Company■ Mixed
New Phase 3 trial: Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes — Amgen
KINDCompany
DIRECTION■ Mixed
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-10-08 12:00 UTC
LAST UPDATE2026-10-08 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Amgen's head-to-head Phase 3 against semaglutide signals direct competition in the GLP-1 diabetes market.
Amgen challenges semaglutide head-to-head in diabetes
CATALYST TO WATCH
Trial enrollment and interim data
MAIN RISK
Trial design or enrollment delays
FULL DISPATCH
Sponsor: Amgen; Status: Not Yet Recruiting; Conditions: Diabetes Mellitus, Type 2; Interventions: Maridebart cafraglutide, Semaglutide; Enrollment: 1300 (estimated); First posted: 2026-10-08; NCT: NCT07866066
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDEli Lilly · LLY
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Phase 3 results posted: Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD) — PTC Therapeutics2026-10-08 12:00 UTC
Phase 3 results posted: Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD) — PTC Therapeutics2026-10-08 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems — Bayer2026-10-08 12:00 UTC
Phase 3 results posted: A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems — Bayer2026-10-08 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: Safety Study of Viaskin Peanut to Treat Peanut Allergy — DBV Technologies2026-10-08 12:00 UTC
Phase 3 results posted: Safety Study of Viaskin Peanut to Treat Peanut Allergy — DBV Technologies2026-10-08 12:00 UTC
→CORRELATIONshares Healthcare
Telix Pharmaceuticals: Merger Bodes Well For Long-Term Plan (NASDAQ:TLX)2026-10-08 15:31 UTC
Telix Pharmaceuticals: Merger Bodes Well For Long-Term Plan (NASDAQ:TLX)2026-10-08 15:31 UTC
→CORRELATIONshares Healthcare
Apodex Opens Free AI Computing Services to Accelerate Drug Research2026-10-08 17:25 UTC
Apodex Opens Free AI Computing Services to Accelerate Drug Research2026-10-08 17:25 UTC
→CORRELATIONshares Healthcare
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules2026-10-08 17:30 UTC
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules2026-10-08 17:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.